Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Raw Materials (2016 - 2019)

Ironwood Pharmaceuticals' Raw Materials history spans 4 years, with the latest figure at $65000.0 for Q4 2019.

  • For Q4 2019, Raw Materials changed N/A year-over-year to $65000.0; the TTM value through Dec 2019 reached $65000.0, changed N/A, while the annual FY2019 figure was $65000.0, N/A changed from the prior year.
  • Raw Materials for Q4 2019 was $65000.0 at Ironwood Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $1.5 million in Q1 2017 and bottomed at $65000.0 in Q4 2019.
  • The 4-year median for Raw Materials is $801500.0 (2016), against an average of $800750.0.
  • The largest annual shift saw Raw Materials plummeted 79.64% in 2018 before it skyrocketed 378.9% in 2019.
  • A 4-year view of Raw Materials shows it stood at $1.0 million in 2016, then soared by 49.8% to $1.5 million in 2017, then tumbled by 79.64% to $308000.0 in 2018, then tumbled by 78.9% to $65000.0 in 2019.
  • Per Business Quant, the three most recent readings for IRWD's Raw Materials are $65000.0 (Q4 2019), $1.1 million (Q3 2019), and $1.5 million (Q2 2019).